Cantitate/Preț
Produs

New Trends in Cancer for the 21st Century: Advances in Experimental Medicine and Biology, cartea 532

Editat de Antonio Llombart-Bosch, Vicente Felipo
en Limba Engleză Hardback – 30 iul 2003
Given the latest advances in cancer research, which includes basic research and its derived diagnostic, clinical, and therapeutic applications, the book New Trends in Cancer for the 21st Century is written by individuals such as molecular biologists, whose tasks are to decipher, after sequencing the human genome, those new genes and pathways involved in the carcinogenesis process; clinical and molecular pathologists, who apply these discoveries for the molecular diagnosis and characterization of the tumor; and clinical oncologists, who treat patients. Pharmacogenetics introduces new perspectives in the translational fields with the design of drugs against specific targets, which at this moment are in clinical trials phases. Several organizations such as the EORTC (European Organization for Research and Treatment of Cancer) and the OECI (Organization of European Cancer Institutes) and comprehensive cancer centers play a crucial role in focusing cancer research on all these areas. This book achieves a state of the art in every field of cancer research and discusses the new perspectives that will open the future for cancer treatment (basic research, new technologies, new drugs, therapies...). For this reason, the book is intended for pathologists, clinicians, and biologists, as well as fellows and students of physiology and medicine.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 36723 lei  6-8 săpt.
  Springer Us – 12 oct 2012 36723 lei  6-8 săpt.
Hardback (1) 57539 lei  6-8 săpt.
  Springer Verlag – 30 iul 2003 57539 lei  6-8 săpt.

Din seria Advances in Experimental Medicine and Biology

Preț: 57539 lei

Preț vechi: 67692 lei
-15% Nou

Puncte Express: 863

Preț estimativ în valută:
11017 11472$ 9141£

Carte tipărită la comandă

Livrare economică 12-26 februarie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780306477621
ISBN-10: 0306477629
Pagini: 293
Dimensiuni: 156 x 234 x 21 mm
Greutate: 0.61 kg
Ediția:1st edition
Editura: Springer Verlag
Colecția Springer
Seria Advances in Experimental Medicine and Biology

Locul publicării:Boston, MA, United States

Public țintă

Professional/practitioner

Cuprins

Driving the Cell Cycle to Cancer.- Proliferation: The Cell Cycle.- Molecular Analysis of Gene Expression in Tumor Pathology.- Ewing Tumor Biology: Perspectives for Innovative Treatment Approaches.- Cancer Epigenetics: DNA Methylation and Chromatin Alterations in Human Cancer.- Molecular Analysis of Cancer Using DNA and Protein Microarrays.- Proteomic Approaches to the Diagnosis, Treatment, and Monitoring of Cancer.- Structural Basis of Tumoral Angiogenesis.- Matrix Metalloproteinases and Tumor Progression.- Angiogenesis Inhibitors and Their Therapeutic Potentials.- Mutated Tyrosine Kinases as Therapeutic Targets in Myeloid Leukemias.- Targeting PDGF Receptors in Cancer-Rationales and Proof of Concept Clinical Trials.- Immune-Promoted Tumor Cell Invasion and Metastasis. New considerations in cancer therapy.- Improvements of Survival in Nine Phase II Clinical Studies With Different Types of Cancer Upon Anti-Tumor Vaccination with an Autologous Tumor Cell Vaccine Modified by Virus Infection to Introduce Danger Signals.- Causation and Prevention of Solely Estrogen-Induced Oncogenesis: Similarities to Human Ductal Breast Cancer.- Cyclooxygenase-2 Inhibitors in Cancer Prevention and Treatment.- Exosomes for Immunotherapy of Cancer.- Breast Cancer Gene Expression Analysis ¡ª The Case for Dynamic Profiling..- Development of the Epidermal Growth Factor Receptor Inhibitor TARCEVATm (OSI-774).- Gefitinib (TRESSA, ZD 1839) for Non-Small Cell Lung Cancer (NSCLC): Recents Results and Further Strategies.- Mechanism of Action of Anti-HER2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2C4.- EORTC Research and Development: Achievements and Future Perspectives.- Contributors.